Meet your world class team

Partners4Access > About us > Meet your world class team
sophie
Sophie Schmitz |  Managing Partner

Sophie is Managing Partner at Partners4Access, the global access experts for orphan drugs, cell and gene therapy. She brings a wealth of commercial and access experience across orphan and cell and gene therapies to the benefit of clients. She plays an active role in advising clients on price and market access strategies, with the ultimate goal of optimizing fair access for all stakeholders in rare disease. Her 20+ year career spans various disease areas and medical devices, successfully supporting the strategy development and operationalisation for orphan drugs. Her extensive industry experience across several product launches ensures clients benefit from that knowledge and build stronger access strategies as a result. Managing global, regional and local teams has provided her with the know-how to successfully face the real-life challenges in today’s orphan, cell and gene therapy world.

Email Sophie

Stuart
Stuart Tutt | Senior Advisor

Stuart has worked in global and European pricing and market access for over 20 years.

Following the acquisition of PriceSpective by ICON in 2012, he was the European Head and Global Head of the Pricing and Market Access consulting team. He has led consulting projects for several large, medium and small biopharma companies, across a wide range of therapy areas and all phases of development, with a focus on in-licensing evaluations, Phase III planning, launch pricing and market access and loss of exclusivity planning. In addition, he has led projects advising clients on internal process and infrastructure.

During his industry tenure, he has worked at GSK where responsibilities included pricing and reimbursement strategy for pipeline products, price management of marketed products and managing the in-house price database. Stuart has a degree in mathematics from Oxford University and a masters in Operational Research.

Email Stuart

christina
Christina Poschen | Consultant

Christina’s expertise includes building market access and policy strategies for rare disease and cell and gene therapy clients. She has experience across various therapy areas including oncology, haematology, neurology and genetic diseases.

Previously, Christina has worked within the pharmaceutical idustry and a trade association which represented small and medium sized bio tech companies at European level. In addition she brings a wealth of global and regional policy and market access communication and marketing experience gained at Edelman.

Christina holds a BSc in Public Health and a Master of Science in Health Economics and Policy, she is fluent in English and German.

Email Christina

aparna
Aparna Krishnan | Corporate Affairs Lead

Aparna has over 10 years’ experience in the pharmaceutical and healthcare industry. Her primary focus is on strategic corporate engagement, public affairs, operations and brand awareness. She has previously worked as Manager, Life Sciences at IHS Markit and as Consultant at Parexel’s Commercialization unit among others specializing in market access, pricing and reimbursement. Aparna has a Bachelors’ degree in Life Sciences and a Masters in International Finance, with a focus on econometric modelling on the pharmaceutical industry.

Email Aparna

nader
Nader Murad | Senior Analyst

Nader has developed expert knowledge and skills in Orphan Drug PRMA Strategy, Access Excellence, and Rare Disease Foresight. He has been particularly involved in value message development, research analysis and testing for orphan drugs and cell and gene therapies in many therapeutic areas optimizing client burden of disease communication; and competitor landscape analysis.

Nader previously worked as Competitive Intelligence analyst at a leading pharmaceutical strategic intelligence firm. He holds an MSc in International Healthcare Management from Imperial College and is fluent in both English and Arabic.

Email Nader

joana
Joanna Fernandes | Analyst

Joanna’s main responsibilities at P4A include developing current and future landscape assessments, market research, and funding analysis, including innovative payment methods. Her key focus is on Cell and Gene therapy but has worked on a number of projects across a range of therapy areas, including immune-oncology, rare and ultra-rare diseases. She has completed a B.Sc. in Biochemistry at Imperial College London, focusing on infectious diseases and biotechnology. Prior to Partners4Access, she worked as an analyst at Finalta, Mckinsey Solutions, allowing her to further develop her primary and secondary research skills.

Email Joana

max
Maximus Rex | Analyst

Max works on a range of projects including primary and secondary research, writing and testing value propositions and preparing landscape assessments to support the development of market access strategies for clients in the biotechnology and pharmaceutical industries. He has a keen interest in Cell and Gene therapy. Prior to joining P4A, he worked as an analyst at McKinsey, having previously completed a Research Master’s in Molecular and Cellular Biosciences and a BSc in Biochemistry at Imperial College London. He carried out research on a variety of topics, including identifying novel targets for a malaria vaccine and researching the mechanisms by which pathogens evade the immune response in humans.

Email Max

OUR PARTNERS

Preeti Patel

Preeti is a clinical pharmacist with over 15 years of experience in pricing and reimbursement systems and solutions and has directed engagements throughout Europe, BRIC, and Asia, creating solutions to some of the most challenging business situations. She has led and directed teams on a variety of strategic and implementation projects and is passionate about helping companies resolve pricing challenges by championing the use of innovative solutions. Preeti heads up Global Pricing Innovations, who have a strategic partnership with P4A to support price modelling and competitor insights. Prior to setting up this venture, she worked as a Vice President at a US consulting firm heading up the global pricing practice.

Julie Brennan

As an associate of P4A, Julie provides an in-depth understanding of the complex matrix that determines optimal market access in the U.K. She has spent the last 20 years working in the pharmaceutical industry as part of numerous commercialisation and launch execution teams and latterly as a consultant supporting clients to achieve the optimal access for their assets. Julie is passionate about bringing the strategy to life through excellence in HTA planning and implementation, value communications and payer-stakeholder engagement.

Anthony G. Bower, PhD

Anthony focuses on improving commercial effectiveness via insights and actions implemented at the executive level. The chief, but not only, focus in improving commercial effectiveness is by gaining and maintaining US and global market access. Anthony has held industry leadership positions in the East Coast, California, and in Europe at, respectively, Synageva, ALZA and Amgen. In addition to over 10 years of experience in industry and several years in consulting, he spent a decade at RAND. Anthony has a doctorate in Economics from the Stanford Graduate School of Business.

Justin Stindt

Justin supports pharma and biotech clients with Market Access strategy and execution. This includes strategy development, payer insight & engagement and project management support to produce local market access deliverables. He has worked in various Market Access and Commercial Director roles at GlaxoSmithKline with international responsibilities for Market Access and pricing strategies, evidence generation to meet payer requirements, product launches and commercial strategy for pipeline assets.

Joel Owerbach

Joel has over 40 years of experience in U.S. managed care pharmacy. He was most recently Vice President, Health Policy-Strategy for Alliance Life Sciences Consulting Group (ALSCG), a global innovative management and technology consultancy, and formerly Vice President, Chief Pharmacy Officer, for Excellus Health Plans, NY.

As one of the early innovators in the development of clinical pharmacy programs within managed care, he has pioneered numerous clinical management and specialty programs, including Drug Information (1977), Pharmacokinetic evaluation program (1978), Anticoagulation Services (1979), Home Intravenous Therapy Service (1982), and Terminal Care/hospice programs (1984) among others. He has worked with a number of pharmaceutical companies, assessing US pharmaceutical market access potential for Phase I-III drugs, including specialty products, orphan drugs, and biosimilars. He has participated in and managed multiple advisory boards and has developed databases and applications profiling and tracking the new Health Care Exchange payer, benefits, and formulary information.

Steve O’Malley

Steve’s pharmaceutical career has been built on a keen understanding of US Managed Markets. Over the last 27 years Steve has built strong relationships with US Payers across channels including commercial, government and hospital. His main areas of expertise are managed care strategy and launches, global pricing and market access, contracting, innovative contracting and partnership, traditional and specialty distribution, payer lead for multiple launches including joint venture management and development and management of pricing committees BD. Steve currently heads MKO Group in the US.

All Rights Reserved ©   Privacy   Partners 4 Access 2018